<scp>KRAS<sup>G</sup></scp><sup>12<scp>C</scp></sup>‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening

Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, emphasizing the urgent need for effective therapies. The predominant driver in PDAC is mutated KRAS proto-oncogene, KRA, present in 90% of patients. The emergence of direct KRAS inhibitors presents a promising avenue for treatment, particularly those targeting the KRAS<sup>G12C</sup> mutated allele, which show encouraging results in clinical trials. However, the development of resistance necessitates exploring potent combination therapies. Our objective was to identify effective KRAS<sup>G12C</sup>-inhibitor combination therapies through unbiased drug screening. Results revealed synergistic effects with son of sevenless homolog 1 (SOS1) inhibitors, tyrosine-protein phosphatase non-receptor type 11 (PTPN11)/Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, and broad-spectrum multi-kinase inhibitors. Validation in a novel and unique KRAS<sup>G12C</sup>-mutated patient-derived organoid model confirmed the described hits from the screening experiment. Our findings propose strategies to enhance KRAS<sup>G12C</sup>-inhibitor efficacy, guiding clinical trial design and molecular tumor boards.

Authors

Institutions

Publication Details

Journal
Molecular Oncology
Published
2024-09-10
DOI
https://doi.org/10.1002/1878-0261.13725
Citations
10
Primary Topic
Protein Tyrosine Phosphatases
Type
article
Field-Weighted Citation Impact
2.34

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening

Constanza Tapia Contreras, Michael B. Ghadimi, Lukas Krauß, Matthias Wirth et al.
10 citations
Molecular Oncology
Protein Tyrosine Phosphatases
2.34
article

KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening

Constanza Tapia Contreras, Michael B. Ghadimi, Lukas Krauß, Matthias Wirth, Ulrich Sax, Tim Beißbarth, Denise Müller, Jochen Gaedcke, Lena‐Christin Conradi, Philipp Ströbel, Silke Kaulfuß, Christian Schneeweis, Melanie Spitzner, Marian Grade, Elisabeth Heßmann, Volker Ellenrieder, Carolin Schneider, Tiago De Oliveira, Jonas Hügel, Maximilian Reichert, Kimia Mirzakhani, Xin Fang, Engin Demirdizen, Gabriela Salinas, Bernd Wollnik, Günter Schneider, Sophia Rheinländer, Karly Conrads, Dieter Saur, Jonas Dominik Falke, Dana‐Magdalena Seifert, Nils Beyer
article en
10 citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, emphasizing the urgent need for effective therapies. The predominant driver in PDAC is mutated KRAS proto-oncogene, KRA, present in 90% of patients. The emergence of direct KRAS inhibitors presents a promising avenue for treatment, particularly those targeting the KRAS<sup>G12C</sup> mutated allele, which show encouraging results in clinical trials. However, the development of resistance necessitates exploring potent combination therapies. Our objective was to identify effective KRAS<sup>G12C</sup>-inhibitor combination therapies through unbiased drug screening. Results revealed synergistic effects with son of sevenless homolog 1 (SOS1) inhibitors, tyrosine-protein phosphatase non-receptor type 11 (PTPN11)/Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, and broad-spectrum multi-kinase inhibitors. Validation in a novel and unique KRAS<sup>G12C</sup>-mutated patient-derived organoid model confirmed the described hits from the screening experiment. Our findings propose strategies to enhance KRAS<sup>G12C</sup>-inhibitor efficacy, guiding clinical trial design and molecular tumor boards.

Molecular OncologyVol. 19(2)
German Cancer Research Center (DE), TUM Klinikum (DE), Humboldt-Universität zu Berlin (DE), Universitätsmedizin Göttingen (DE), Institute of Clinical Cancer Research (DE), Nanoscale Microscopy and Molecular Physiology of the Brain Cluster of Excellence 171 — DFG Research Center 103 (DE), Technical University of Munich (DE), University of Göttingen (DE), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE)
Wilhelm Sander-Stiftung, Deutsche Forschungsgemeinschaft, Volkswagen Foundation, Bundesministerium für Bildung und Forschung, Deutsche Krebshilfe, Deutschen Konsortium für Translationale Krebsforschung, Bayerische Staatsministerium für Wirtschaft, Landesentwicklung und Energie
Good health and well-being
Openalex Percentile: Top 11%
Protein Tyrosine Phosphatases
2.34
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.